First Line Mantle Cell Lymphoma (MCL) Treatment by RiBVD Schema in Patients Older Than 65 Years or 18 to 65 Years Old Who Can't or Refuse Receive Conditioning Regimen Followed by Autograft.
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2016
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Dexamethasone; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms RIBVD
- 20 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 26 Oct 2011 New trial record